Two from UK join Caligor Rx in US

Will lead quality assurance and clinical trial supplies

Caligor Rx, a global clinical trial procurement company based in New York, US, has appointed Jess McKenna as head of quality assurance and customer relationships and Jacquelyn May as head of clinical trial supplies. The two women join Caligor Rx, as a team, after having spent five years working together for a UK supplier of clinical trial supplies.

McKenna has a first class degree in Health and Social Care from the Open University in the UK. She was most recently responsible for building a quality assurance department at a supplier of comparator drugs.

May is a registered nurse and joins Caligor Rx after five years in comparator procurement for worldwide clinical trials. She was previously a senior manager in the NHS in the UK.

You may also like

Regulatory

Diversis Capital acquires Caligor Rx

Caligor sources and distributes comparator drugs for clinical trials worldwide from the US and UK
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

How the QA and QP talent market is changing in pharma

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
Regulatory

Andelyn Biosciences strengthens CDMO credentials with full ICMC certification

The certification received by Andelyn underscores their long-standing commitment to quality, operational readiness, and client service as the company supports innovators in advancing gene therapies from development through clinical and commercial manufacturing
Regulatory

MHRA approves beremagene geperpavec gene therapy gel for DEB from birth

The MHRA has approved beremagene geperpavec (Vyjuvek), a topical gene therapy gel for wounds in patients with dystrophic epidermolysis bullosa (DEB), for use from birth onwards
Regulatory

FDA approves AstraZeneca's FASENRA for hypereosinophilic syndrome

AstraZeneca's FASENRA has received FDA approval for hypereosinophilic syndrome in adults and adolescents aged 12 and above, based on Phase III NATRON trial data showing a 65% reduction in the risk of first HES flare compared to placebo
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Subscribe now